INJECTION FREQUENCY AND PROGNOSTIC FACTORS IN A TREAT-AND-EXTEND REGIMEN OF INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

被引：0
|
作者：
Narayan, Daniel [1 ]
Muecke, James [1 ]
机构：
[1] Univ Adelaide, Adelaide, SA, Australia
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2013年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：106 / 106
页数：1
相关论文
共 50 条
  • [31] Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen
    Rayess, Nadim
    Houston, S. K. Steven, III
    Gupta, Omesh P.
    Ho, Allen C.
    Regillo, Carl D.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (01) : 3 - 8
  • [32] Psychological impact of treat-and-extend ranibizumab therapy in patients with age-related macular degeneration
    Kuwayama, Satoshi
    Kato, Aki
    Yasukawa, Tsutomu
    Sugita, Iichiro
    Yoshida, Munenori
    Nozaki, Miho
    Hirano, Yoshio
    Kondo, Junko
    Abe, Tomohiro
    Sugita, Kimiko
    Okita, Takahide
    Morita, Hiroshi
    Sugitani, Kazuhiko
    Inoue, Naomi
    Takase, Noriaki
    Ogura, Yuichiro
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [33] TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The Importance of Baseline Characteristics
    Rush, Ryan B.
    Simunovic, Matthew P.
    Vandiver, Lorelei
    Aragon, Antonio V., II
    Ysasaga, Jason E.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (05): : 846 - 852
  • [34] Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease
    Kertes, Peter J.
    Galic, Ivan J.
    Greve, Mark
    Williams, R. Geoff
    Rampakakis, Emmanouil
    Scarino, Andrea
    Sheidow, Tom
    OPHTHALMOLOGY, 2019, 126 (06) : 841 - 848
  • [35] One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration
    Hidetaka Matsumoto
    Junki Hoshino
    Kosuke Nakamura
    Hideo Akiyama
    Japanese Journal of Ophthalmology, 2024, 68 : 83 - 90
  • [36] Cost-Benefit Analysis of Intravitreal Anti-VEGF Medications for the Treatment of Neovascular Age-Related Macular Degeneration in a Treat-And-Extend Regimen
    Carey, Andrew
    Russell, Stephen R.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [37] EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The ARIES Study: A Randomized Clinical Trial
    Mitchell, Paul
    Holz, Frank G.
    Hykin, Philip
    Midena, Edoardo
    Souied, Eric
    Allmeier, Helmut
    Lambrou, George
    Schmelter, Thomas
    Wolf, Sebastian
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (09): : 1911 - 1920
  • [38] Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration
    Hatz, Katja
    Pruente, Christian
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2016, 100 (10) : 1341 - 1345
  • [39] Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients
    Ishibashi, Koki
    Haruta, Masatoshi
    Ishibashi, Yumi
    Noda, Rie
    Dake, Shotaro
    Yoshida, Shigeo
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2021, 13
  • [40] Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results
    N Homer
    D S Grewal
    R G Mirza
    A T Lyon
    M K Gill
    Eye, 2015, 29 : 1152 - 1155
12345